DTIL - Rasio cepet Precision BioSciences, Inc.

Precision BioSciences (DTIL) creates scalable genome editing tools, generating profit through licensing agreements with major corporations. Simultaneously, the company minimizes risks by focusing on the therapy of hereditary pathologies and the fight against viral infections. The current indicator is 12.24, which is confirmed by the price chart located below that clearly demonstrates the changes.

Precision BioSciences' large-scale genome editing developments in collaboration with Novartis and Eli Lilly require significant operating expenses. By analyzing the quick liquidity ratio, an investor assesses the company's ability to cover short-term obligations solely through cash and accounts receivable, excluding illiquid inventories. Growth in this indicator confirms financial autonomy and reduces default risks during the implementation of high-tech projects.